is trulicity a glp-1 inhibitor Semaglutide vs. Other Receptor Agonists GLP-1 receptor agonists and next-generation

Without medical oversight, side effects can go unnoticed until they become severe

The Lancet Diabetes & Endocrinology , 2017;5(5):355-366

Not managing side effects and relying on GLP-1 processed foods is another mistake

Drug Discov

RV-8451, differentiated oral, muscle-preserving GLP-1 candidate for obesity Recent Highlights: In February 2026, Rivus stated it was entering a pivotal year, advancing HU6 in the AMPLIFY Phase 2 MASH trial while preparing the first clinical trial for RV-8451, its muscle-preserving oral GLP-1 candidate, designed to address the muscle-loss criticism leveled at existing GLP-1 therapies

While GLP-1s are commonly used by perimenopausal women, this population has been largely ignored in studies of the drugs' risks and benefits